Study of CD184 (CXCR4) Expression in Chronic Lymphocytic Leukemia Patients

Nabila Reda Diab;

Abstract


Chronic lymphocytic leukemia (CLL) is a prevalent malignant tumor characterized by CLL cells homing in the bone marrow microenvironment.
CXCR4 (CD184) is a chemokine and chemokine receptor pair playing critical roles in tumor genesis. It is over expressed in many hematological malignancies including acute myeloid leukemia, chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and generally correlates with a poor prognosis (Li et al., 2016).
So, the present study aimed to determine clinical utility of CD184 in CLL patients in predicting disease outcome and planning treatment regimen. The study recruited 33 patients with CLL. They were subjected to careful history taking, thorough clinical and laboratory investigations including serological assessment of CD184.
Patients included in the present study comprised 21 males (63.6%) and 12 females (36.4%) with a mean age of 53.798.05 years. Documented patients’ history in the current study revealed that just 1 patient (3.0%) had hypertension while 5 patients (15.2%) had diabetes mellitus
On examination, 5 patients (15.2%) of our series had lymphadenopathy, 6 patients (18.2%) had hepato-splenomegaly and 19 patients (57.6%) had positive B symptoms.
Regarding laboratory data, patients included in the current study had hemoglobin level of 10.65 ± 3.04 gm/dl,


Other data

Title Study of CD184 (CXCR4) Expression in Chronic Lymphocytic Leukemia Patients
Other Titles دراسة تعبير معامل سى دى 184 (سى إكس سى آر 4) فى مرضى اللوكيميا الليمفاوية المزمنة
Authors Nabila Reda Diab
Issue Date 2017

Attached Files

File SizeFormat
J7093.pdf739.24 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 3 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.